Clinical effects and biomarkers of biological agents on asthma

Not Applicable

• Conditions: Bronchial asthma; asthma; D001249

• Registration Number: JPRN-jRCT1031190033
• Lead Sponsor: MORI AKIO

Brief Summary

Biomarkers associated with the effects of biological agents were aimed by the current investigation, which was unfortunately suspended due to the quit of the supporting grant. Further enrollment or follow up of the patients was not possible. Biomarkers associated with the biological agents would greatly ease economical and clinical needs in this field.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-05-28
• Study Completion: 2021-03-31
• Last Update Posted: 20 November 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

1) Asthma patients diagnosed based on Japanese Asthma Prevention and Management Guideline 2018 who are older than 12 years old
2) Either anti-IgE antibody (Zorea), anti-IL-5 antibody (Nucala), or anti-IL-5 receptor antibody (Facenra) is going to be administered.
3) Written informed consent from the patients or the legal gardian is obtained.

Exclusion Criteria

1) Those patients who can not be taken blood sample
2) Those patients who were judged not suitable for the entry to this investigation be the responsible doctor

Study & Design

• Study Type: Interventional
• Study Design: Not specified